Adding active vitamin D to the COVID-19 treatment regimen in our setting reduced the PSI at discharge when patients either required supplemental oxygen or high-dose corticosteroid therapy or had a high CRP concentration (> 30 mg/L) at treatment initiation. The gene discussed is CRP; the disease is COVID-19.